CDEK by Data4ThePeople
IndicationsMechanismsTrialsFDA ApprovalsAbout
Sign in Sign up
IndicationsMechanismsTrialsFDA ApprovalsAbout

← D3A.0

Chapter 2 - Neoplasms (C00-D49)»Benign neuroendocrine tumors (D3A)»Benign carcinoid tumors of other sites (D3A.09)

D3A.09

Benign carcinoid tumors of other sites

Sub-codes (8)

  • D3A.090 Benign carcinoid tumor of the bronchus and lung
  • D3A.091 Benign carcinoid tumor of the thymus
  • D3A.092 Benign carcinoid tumor of the stomach
  • D3A.093 Benign carcinoid tumor of the kidney
  • D3A.094 Benign carcinoid tumor of the foregut, unspecified
  • D3A.095 Benign carcinoid tumor of the midgut, unspecified
  • D3A.096 Benign carcinoid tumor of the hindgut, unspecified
  • D3A.098 Benign carcinoid tumors of other sites

CDEK

The Clinical Drug Experience Knowledgebase — tracking drugs, sponsoring organizations, and clinical trials from first-in-human testing through approval.

Browse

  • Drugs
  • Organizations
  • Trials

About

  • About CDEK
  • Glossary

Built and maintained by Data4ThePeople.

YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED "AS IS", WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.